CarbonBridge
CarbonBridge Inc. is a New York-based, pre-revenue biotech developing a proprietary direct-gas bioreactor platform that eliminates solubility barriers to convert methane and CO2 into chemicals like methanol for bio-industrial customers in fuels, agricultural chemicals, and polymers.
- Company typePrivate
- Founded2021
- HeadquartersNewark, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CarbonBridge does
CarbonBridge Inc. is a privately held, venture-backed biotechnology company founded in 2021 and headquartered at 1361 Amsterdam Ave., Suite 530, New York, NY, that develops a direct-gas bioprocessing bioreactor platform for converting gaseous feedstocks (methane and CO2) into chemicals such as methanol. The company's core technology eliminates traditional solubility barriers in gas fermentation by enabling microbes to interact directly with gas feedstock without aqueous media, spargers, bubbles, agitators, or high pressures; the company claims this architecture delivers 5x greater productivity than the next-best bioreactor, sub-60-second environmental changeover, and modular scalability through stacking in parallel or series.
The product portfolio centers on the DGF-100 Direct-Gas Bioreactor and the Bring-Your-Own-Bug Platform, which lets customers supply their own microbial strains while using CarbonBridge's proprietary direct-gas hardware. The stated revenue mechanics combine bioreactor hardware sales and bioprocessing services, with pricing conducted through a quote-based early-access intake rather than public list pricing. The go-to-market is enterprise field sales targeting bio-industrial customers in alternative fuels, food and feed chemicals, and polymer intermediates, supplemented by conference presence (ARPA-E 2026 Summit, BioMADE Member Meeting, Global Synthetic Biology Conference) and a content/LinkedIn funnel.
As of the most recent disclosure, the company has 1-10 employees, has raised approximately $840,000 cumulatively across grants and accelerator vehicles (largest tranche being the August 2024 ARPA-E award of $719,881, with prior accelerator exposure to IndieBio Class 07, Techstars, SOSV HAX, and Brinc), and has no disclosed revenue or ARR. The company is currently in a pre-commercial validation phase, executing pilot demonstrations with RTI International (methanol-from-methane, North Carolina Pilot Xcelerator, announced May 2026), A*STAR ISCE2 (CO2 utilization, announced April 2026), and Lawrence Berkeley National Laboratory (biosurfactants from agricultural sidestreams, BEAM Circular-funded, announced January 2026), while explicitly seeking active investors and bio-industrial business partners. Co-founder Sophia Xu was named to Forbes 30 Under 30 in December 2025.
CarbonBridge firmographics
Firmographics- Name
- CarbonBridge
- Legal name
- CarbonBridge Inc.
- Website
- https://carbonbridge.io
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CarbonBridge Inc. is a New York-based, pre-revenue biotech developing a proprietary direct-gas bioreactor platform that eliminates solubility barriers to convert methane and CO2 into chemicals like methanol for bio-industrial customers in fuels, agricultural chemicals, and polymers.
- Ownership category
- akta.pro rank
CarbonBridge industry classification
Industry- Product category
- Industrial Biotechnology / Gas-to-Chemicals Bioprocessing
- NAICS
- Petrochemical Manufacturing (32511), Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing (325194)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- CO₂ Utilization from Bioenergy (CCU: Fuels, Chemicals, Building Materials) (EUAAALAG)
- akta.pro secondary industries
- Biofuels & Renewable Fuels Switching (Biomethane/RNG, Bio-oils, Sustainable Biomass) (EUABAJAD), E‑Fuels & Synthetic Hydrocarbons (e‑kerosene, e‑diesel, e‑gasoline, e‑methane) (EUABAIAA), Bio-based Carbon Products & Advanced Bioproducts (Biochar, activated carbon, carbon black alternatives) (EUAAAIAM)
Keywords
Where CarbonBridge is headquartered
LocationHeadquarters
- HQ city
- Newark
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CarbonBridge business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Bioreactor Hardware Sales: Sale of direct-gas bioreactor systems (DGF-100 model referenced). Customers can evaluate via early access program before scaling.
- Bioprocessing Services: Processing services for converting gas feedstocks (methane, CO₂) into bio-industrial chemicals for customers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CarbonBridge product offering
Product offeringCore offering
CarbonBridge builds and sells direct-gas bioprocessing bioreactors (notably the DGF-100) that use engineered microbes to convert methane into methanol and other bioproducts at near-atmospheric pressure. The company sells the hardware platform to industrial customers and offers a Bring-Your-Own-Bug customization service that lets clients run their own organisms against methane and biogas feedstocks. It also provides bioprocessing R&D and engineering services for bio-industrial applications.
Product overview
CarbonBridge offers a single unified product line centered on its direct-gas bioreactor technology. The core offering is the DGF-100 Direct-Gas Bioreactor — a compact, highly efficient bioreactor that enables microbes to interact directly with gas feedstock without aqueous media, eliminating traditional solubility barriers. The Bring-Your-Own-Bug Platform is the customer-facing model wherein customers provide their own microbial strains while using CarbonBridge's proprietary direct-gas bioprocessing hardware. The Direct-Gas Bioprocessing Platform is the underlying technology framework enabling this capability, featuring modular scalability, sub-60-second process condition changes, and 5x greater productivity than conventional bioreactors. The portfolio supports applications in methanol and alternative fuel production, food and feed chemicals, polymer intermediates, and agricultural biosurfactants.
Differentiator
Problem solved
Functional benefit
Brands
- Bring-Your-Own-Bug Platform: Platform where customers own the biology while CarbonBridge provides the direct gas bioprocessing platform
- DGF-100 bioreactor
Products and services
- DGF-100 Direct-Gas Bioreactor CarbonBridge's flagship direct-gas bioreactor hardware unit, designed to use methanotrophic microbes to convert methane and biogas feedstocks into methanol and other bioproducts at near-atmospheric pressure. Sold to industrial biotech, energy, and waste-management customers that need to monetize or reduce vented methane streams.
- Bring-Your-Own-Bug Platform A customization and service offering that lets biotech R&D teams deploy their own proprietary microbial strains on CarbonBridge's gas-phase bioreactor platform against methane feedstocks, without building in-house gas-phase bioprocessing capability. Targeted at synthetic biology and industrial biotech R&D teams.
Quantifiable outcome
- 5x more productive than the next best bioreactor
- +2 more outcomes
Companies that use CarbonBridge
Customer profileSegments3 records
Ideal customer profiles2 records
CarbonBridge technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CarbonBridge partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- RTI InternationalcoreRTI International and CarbonBridge are collaborating to demonstrate bioprocessing technology at RTI's Pilot Xcelerator in North Carolina. The project will develop data on converting methane into chemicals like methanol, supporting future scale-up and commercialization efforts. The work is designed to generate credible, third-party performance data to support informed decisions about scale-up.
- A*STAR ISCE2coreA*STAR ISCE2 collaborates with CarbonBridge to advance gas fermentation for scalable CO₂ utilization. The collaboration aims to generate insights into reactor performance and key operating parameters relevant to future scale-up considerations, supporting industrially relevant CO₂-to-X bioprocessing pathways.
- Lawrence Berkeley National LaboratorycoreResearch partnership with Lawrence Berkeley National Laboratory funded by BEAM Circular, aimed at developing alternative biosurfactants from agricultural sidestreams.
- BioMADEminorCarbonBridge attends BioMADE Member Meeting as part of their industry engagement. BioMADE is a Manufacturing Innovation Institute focused on bioindustrial manufacturing.
- IndieBiominorCarbonBridge is associated with IndieBio startup accelerator, which provides support and ecosystem connections for bio startups.
- ARPA-EminorARPA-E (Advanced Research Projects Agency-Energy) supports energy technology startups. CarbonBridge attends ARPA-E 2026 Summit and is listed as a partner/portfolio company.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
CarbonBridge competitors and assessment
Company assessmentDirect peers
- String Bio: String Bio uses proprietary gas-fermentation platforms to convert methane and other industrial gases into specialty chemicals and proteins. Like CarbonBridge, it is a developer of microbial gas-to-product bioprocessing, though with a different downstream product mix.
- Kiverdi: Kiverdi develops gas-fermentation and carbon-capture bioprocessing technologies to convert CO2 and other gases into oils, proteins, and chemicals. It overlaps directly with CarbonBridge's methane/CO2-to-chemicals platform thesis and similarly targets industrial bio applications.
- Newlight Technologies: Newlight commercializes a gas-to-biopolymer process using microbes that convert greenhouse gases into PHB-based materials. It addresses the same 'gas-to-chemical via microbes' value chain CarbonBridge targets, with downstream focus on polymer intermediates.
- LanzaTech: LanzaTech is the commercial leader in gas fermentation, converting CO and CO2 (including captured industrial emissions) into fuels and chemicals using acetogenic microbes. It is the most direct competitor to CarbonBridge's gas-to-chemicals thesis and operates at significantly larger scale with established offtakes.
Broad incumbents
- Ginkgo Bioworks: Ginkgo Bioworks is a broad synthetic biology platform developing engineered microbes for industrial bioprocessing across fuels, chemicals, and consumer products. While not solely gas-fermentation-focused, its organism engineering capabilities intersect with CarbonBridge's BYOB (Bring-Your-Own-Bug) model.
Emerging players
- ZymoChem: ZymoChem uses engineered microbes and gas-fermentation approaches to produce chemicals from C1 feedstocks. Comparable in stage and architectural ambition to CarbonBridge, though focused on specific chemical outputs rather than a general-purpose reactor platform.
- Bota Bio: Bota Bio is an industrial bioprocessing company developing microbial production routes to specialty chemicals and ingredients. Comparable as an early-stage bioprocessing platform competing for similar bio-industrial customer relationships.
- Arctus Therapeutics: Arctus is developing bioprocessing technologies that leverage engineered biology and catalytic conversion of waste gases into fuels and chemicals, intersecting with CarbonBridge's methane-utilization value proposition.
- Jupiter Ionics: Jupiter Ionics focuses on electrochemical and biological conversion of greenhouse gases, including CO2-to-chemical pathways. It is adjacent to CarbonBridge in the broader C1-to-products landscape and competes for similar decarbonization customer budgets.
- Solaris Biotech: Solaris Biotech designs and manufactures bioreactors and bioprocessing equipment for industrial biotechnology applications. It overlaps with CarbonBridge on the bioreactor hardware side, though with conventional stirred-tank systems rather than direct-gas processing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
CarbonBridge social profiles
Digital presenceCarbonBridge financial estimates
Financial estimateRevenue estimate
Valuation estimate
CarbonBridge leadership team
Management profileNumber of profiles
Profiles2 records
CarbonBridge funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CarbonBridge M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CarbonBridge
What does CarbonBridge do?
CarbonBridge builds and sells direct-gas bioprocessing bioreactors (notably the DGF-100) that use engineered microbes to convert methane into methanol and other bioproducts at near-atmospheric pressure. The company sells the hardware platform to industrial customers and offers a Bring-Your-Own-Bug customization service that lets clients run their own organisms against methane and biogas feedstocks. It also provides bioprocessing R&D and engineering services for bio-industrial applications.
Is CarbonBridge a public or private company?
CarbonBridge is a private company. It is classified as venture growth investor backed and is currently operating.
When was CarbonBridge founded?
CarbonBridge was founded in 2021. It employs 1 to 10 people.
Where is CarbonBridge based?
CarbonBridge is headquartered in Newark, United States, in the North America region.
How does CarbonBridge make money?
Two revenue lines are on record. Bioreactor Hardware Sales are the primary driver. The others are bioprocessing Services.
Who are CarbonBridge's main competitors?
Direct peers on record are String Bio, Kiverdi, Newlight Technologies and LanzaTech. Ginkgo Bioworks is listed as a broad incumbent. Emerging players are ZymoChem, Bota Bio, Arctus Therapeutics, Jupiter Ionics and Solaris Biotech.
Does CarbonBridge have an API?
No public API is recorded for CarbonBridge.
What industry is CarbonBridge in?
CarbonBridge's product category is Industrial Biotechnology / Gas-to-Chemicals Bioprocessing. Its primary akta.pro industry code is EUAAALAG, CO₂ Utilization from Bioenergy (CCU: Fuels, Chemicals, Building Materials), with a secondary code of EUABAJAD, Biofuels & Renewable Fuels Switching (Biomethane/RNG, Bio-oils, Sustainable Biomass). Its NAICS code is 32511 and its SIC code is 8731.